ArticleEBioMedicine2016
Circulating Cell Free DNA in the Diagnosis of Trophoblastic Tumors.
Article in EBioMedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- Next-Generation Sequencing Panel Analysis of Clinically Relevant Mutations in Circulating Cell-Free DNA from Patients with Gestational Trophoblastic Neoplasia: A Pilot Study.BioMed research international · 2020Trial
- Successful Diagnosis and Treatment of Early Postpartum Choriocarcinoma.Cancer reports (Hoboken, N.J.) · 2025Article
- Gestational trophoblastic disease: understanding the molecular mechanisms of placental tumours.Disease models & mechanisms · 2025Review
- Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal transduction and targeted therapy · 2024Review
- Sensitive screening of single nucleotide polymorphisms in cell free DNA for diagnosis of gestational tumours.NPJ genomic medicine · 2022Article
- Advances in the diagnosis and early management of gestational trophoblastic disease.BMJ medicine · 2022Review
- Circulating Tumor DNA Testing Supports Rapid Therapeutic Decision-Making in Metastatic Melanoma: A Case Report.Frontiers in oncology · 2022Article
- Hydatidiform mole diagnostics using circulating gestational trophoblasts isolated from maternal blood.Molecular genetics & genomic medicine · 2021Article
- Tumor circulome in the liquid biopsies for digestive tract cancer diagnosis and prognosis.World journal of clinical cases · 2020Review
- The potential of serum fetal DNA for early diagnosis of gestational trophoblastic disease.Turkish journal of obstetrics and gynecology · 2019Article
- Cell-free DNA in cancer: current insights.Cellular oncology (Dordrecht, Netherlands) · 2019Review
- A Review on the Pathogenesis and Clinical Management of Placental Site Trophoblastic Tumors.Frontiers in oncology · 2019Review
- Cell-free DNA in pregnancy with choriocarcinoma and coexistent live fetus: A case report.Medicine · 2016Article
- Circulating Tumor DNA: A Potential Novel Diagnostic Approach in Gestational Trophoblastic Neoplasia.EBioMedicine · 2016Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gestational trophoblastic neoplasia (GTN) represents a group of diseases characterized by production of human chorionic gonadotropin (hCG). Since non-gestational tumors may occasionally secrete hCG, histopathological diagnosis is important for appropriate clinical management. However, a histopathological diagnosis is not always available. We therefore investigated the feasibility of extracting cell free DNA (cfDNA) from the plasma of women with GTN for use as a "liquid biopsy" in patients without histopathological diagnosis. cfDNA was prepared from the plasma of 20 women with a diagnosis of GTN and five with hCG-secreting tumors of unknown origin. Genotyping of cfDNA from the patient, genomic DNA from her and her partner and DNA from the tumor tissue identified circulating tumor DNA (ctDNA) (from 9% to 53% of total cfDNA) in 12 of 20 patients with GTN. In one case without a tissue diagnosis, ctDNA enabled a diagnosis of GTN originating in a non-molar conception and in another a diagnosis of non-gestational tumor, based on the high degree of allelic instability and loss of heterozygosity in the ctDNA. In summary ctDNA can be detected in the plasma of women with GTN and can facilitate the diagnosis of both gestational and non-gestational trophoblastic tumors in cases without histopathological diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.